Abstract:Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c03776?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c03776</a>.Additional figures for further characterization of OMVs and OMV-PD1 (Supplementary Figure 1); BMDCs mature, TLRs response, and CD49b+ NK cells quantification (Supplementary Figures 2, 3, and 4); PD-L1 upregulation in tumor cells in response to OMVs or IFN-γ (Supplementary Figure 5); immunoprecipitation results with OMVs and OMV-PD1 (Supplementary Figure 6); cell-binding and uptake studies (Supplementary Figures 7 and 8); intracellular fate of OMVs and OMV-PD1 (Supplementary Figure 9); proportion of proliferative T cells (Supplementary Figure 10); OMV-PD1 blood retention time (Supplementary Figure 11); cytotoxicity on B16, CT26, and HUVEC (Supplementary Figure 12); B16 and CT26 tumor images and average body weight (Supplementary Figure 13); analysis of effector memory T cells (CD3+CD8+CD44+CD62L–), CD49b+ cells, and CD11b+ cells (Supplementarys Figure 14 and 15); quantification analysis of PDL1 (Supplementary Figure 16); percentage of IFN-γ+CD8+ T cells (Supplementary Figure 17); biosafety of OMVs (Supplementary Figures 18 and 19); effects of immunotherapy on organ histology (Supplementary Figure 20); and Pearson's colocalization coefficiencts (PCC) of PD-L1 and acid compartments (Supplementary Table 1) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c03776/suppl_file/nn0c03776_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1

The Microbiota is a Potential Mediator of the Crosstalk Between Γδ T Cells and Tumors

Microbiota-activated CD103+ DCs Stemming from Microbiota Adaptation Specifically Drive Γδt17 Proliferation and Activation.

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

The intrinsic and extrinsic regulation of γδ-T17 cells through the IL-17-IL-17r axis during homeostasis (LYM2P.729)

PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells

Γδt17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer.

Abstract 6686: The mechanism of gut microbiome-mediated immune activation on the clinical efficacy of PD-1 blocking treatment in solid tumors

Escherichia Coli K12 Upregulates Programmed Cell Death Ligand 1 (PD-L1) Expression in Gamma Interferon-Sensitized Intestinal Epithelial Cells Via the NF-κB Pathway.

Infection and inflammation stimulate expansion of a CD74+ Paneth cell subset to regulate disease progression

γδ T cells and the PD-1/PD-L1 axis: a love–hate relationship in the tumor microenvironment

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

The Microbiota Maintain Homeostasis of Liver-Resident Γδt-17 Cells in a Lipid Antigen/cd1d-Dependent Manner

Integrated Regulation of Toll-like Receptor Responses by Notch and Interferon-γ Pathways

Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice

Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade

Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy

Bacterial peptidoglycan signalling in microglia: Activation by MDP via the NF-κB/MAPK pathway

Programming inflammatory cell death for therapy

Gut Microbiota Defines Functional Direction of Colonic Regulatory T Cells with Unique TCR Repertoires